Literature DB >> 11502658

The occurrence of ventilator-associated pneumonia in a community hospital: risk factors and clinical outcomes.

E H Ibrahim1, L Tracy, C Hill, V J Fraser, M H Kollef.   

Abstract

STUDY
OBJECTIVES: To prospectively identify the occurrence of ventilator-associated pneumonia (VAP) in a community hospital, and to determine the risk factors for VAP and the influence of VAP on patient outcomes in a nonteaching institution.
DESIGN: Prospective cohort study.
SETTING: A medical ICU and a surgical ICU in a 500-bed private community nonteaching hospital: Missouri Baptist Hospital. PATIENTS: Between March 1998 and December 1999, all patients receiving mechanical ventilation who were admitted to the ICU setting were prospectively evaluated. INTERVENTION: Prospective patient surveillance and data collection.
RESULTS: During a 22-month period, 3,171 patients were admitted to the medical and surgical ICUs. Eight hundred eighty patients (27.8%) received mechanical ventilation. VAP developed in 132 patients (15.0%) receiving mechanical ventilation. Three hundred one patients (34.2%) who received mechanical ventilation died during hospitalization. Logistic regression analysis demonstrated that tracheostomy (adjusted odds ratio [AOR], 6.71; 95% confidence interval [CI], 3.91 to 11.50; p < 0.001), multiple central venous line insertions (AOR, 4.20; 95% CI, 2.72 to 6.48; p < 0.001), reintubation (AOR, 2.88; 95% CI, 1.78 to 4.66; p < 0.001), and the use of antacids (AOR, 2.81; 95% CI, 1.19 to 6.64; p = 0.019) were independently associated with the development of VAP. The hospital mortality of patients with VAP was significantly greater than the mortality of patients without VAP (45.5% vs 32.2%, respectively; p = 0.004). The occurrence of bacteremia, compromised immune system, higher APACHE (acute physiology and chronic health evaluation) II scores, and older age were identified as independent predictors of hospital mortality.
CONCLUSIONS: These data suggest that VAP is a common nosocomial infection in the community hospital setting. The risk factors for the development of VAP and risk factors for hospital mortality in a community hospital are similar to those identified from university-affiliated hospitals. These risk factors can potentially be employed to develop local strategies for the prevention of VAP. CLINICAL IMPLICATIONS: ICU clinicians should be aware of the risk factors associated with the development of VAP and the impact of VAP on clinical outcomes. More importantly, they should cooperate in the development of local multidisciplinary strategies aimed at the prevention of VAP and other nosocomial infections.

Entities:  

Mesh:

Year:  2001        PMID: 11502658     DOI: 10.1378/chest.120.2.555

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  45 in total

1.  A prospective, randomized trial of continuous lateral rotation ("kinetic therapy") in patients with cardiogenic shock.

Authors:  Gregor Simonis; Kerstin Steiding; Kerstin Schaefer; Thomas Rauwolf; Ruth H Strasser
Journal:  Clin Res Cardiol       Date:  2012-06-23       Impact factor: 5.460

2.  Assessment of Critical Care Provider's Application of Preventive Measures for Ventilator-Associated Pneumonia in Intensive Care Units.

Authors:  Masoumeh Bagheri-Nesami; Maryam Amiri-Abchuyeh; Afshin Gholipour-Baradari; Jamshid Yazdani-Cherati; Attieh Nikkhah
Journal:  J Clin Diagn Res       Date:  2015-08-01

3.  Risk factors for late-onset ventilator-associated pneumonia in trauma patients receiving selective digestive decontamination.

Authors:  Marc Leone; Stéphane Delliaux; Aurélie Bourgoin; Jacques Albanèse; Franck Garnier; Ioana Boyadjiev; Francois Antonini; Claude Martin
Journal:  Intensive Care Med       Date:  2004-12-02       Impact factor: 17.440

4.  Risk factors and outcome of Ventilator Associated Tracheitis (VAT) in pediatric trauma patients.

Authors:  Maroun J Mhanna; Ibrahim S Elsheikh; Dennis M Super
Journal:  Pediatr Pulmonol       Date:  2012-04-24

5.  Linking joint commission inpatient core measures and national patient safety goals with evidence.

Authors:  Andrew L Masica; Kathleen M Richter; Paul Convery; Ziad Haydar
Journal:  Proc (Bayl Univ Med Cent)       Date:  2009-04

Review 6.  [Ventilator-associated pneumonia].

Authors:  R Dembinski; R Rossaint
Journal:  Anaesthesist       Date:  2008-08       Impact factor: 1.041

7.  Defining, treating and preventing hospital acquired pneumonia: European perspective.

Authors:  Antoni Torres; Santiago Ewig; Harmut Lode; Jean Carlet
Journal:  Intensive Care Med       Date:  2008-11-07       Impact factor: 17.440

8.  Use of ventilator bundle to prevent ventilator associated pneumonia.

Authors:  Sangeet Narang
Journal:  Oman Med J       Date:  2008-04

9.  Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution.

Authors:  Sujata M Bhavnani; Jeffrey P Hammel; Elizabeth A Lakota; M Courtney Safir; Brian D VanScoy; Yu Nagira; Christopher M Rubino; Nobuo Sato; Tomokazu Koresawa; Kenichiro Kondo; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

10.  Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial.

Authors:  Lee E Morrow; Marin H Kollef; Thomas B Casale
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.